About this trial
Multidisciplinary management of amyotrophic lateral sclerosis (ALS) can significantly increase survival but also improve the quality of life of patients. The evaluation of cortical-spinal motor neuron damage is currently based only on the assessment of clinical data. However, the alteration of the central motor pathway and conduction can be identified and quantified by different techniques using motor-evoked potentials (MEP). The combined quadriceps test (QCT) has been developed to assess central and peripheral motor pathway conduction. This test allows to quantify central and peripheral part of a mixed disorder, and to detect physiological hyporeflexia or hyperreflexia which, in the case of suspected ALS, can lead to interpretation problems.
The evolution of the QCT parameters during the course of pathology will lead to determine the preponderance of an initial central involvement, but also its extension throughout the pathology. The study of these parameters as well as the clinical course of the disease could reveal a correlation between peripheral and central involvement. This link would provide arguments in favor of pathophysiological hypotheses of disease onset and progression. From a prognostic point of view and depending on the quantification of central and peripheral involvement, the QCT would make it possible to characterize the different ALS phenotypes. This phenotypic characterization would help identify prognostic factors at diagnosis.
The investigators propose a cohort study with the exploration of central motor neuron damage by QCT during the course of ALS in order to provide arguments for a better mechanistic understanding and follow-up of this disease with a poor prognosis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
A male or female patient of legal age with suspected ALS (bulbar or spinal) who meets the criteria for "possible", "probable" or "definite" ALS according to the Awaji criteria
Able to give informed consent to participate in the research
Enrolled in a Social Security plan
Disqualifiers
Pregnant or breastfeeding woman
Severe progressive pathology other than ALS.
Comorbidities with another neurological disease altering motor skills.
Contraindication to trans-cranial magnetic stimulation: epilepsy, pacemaker, intracranial ferromagnetic foreign body (clip, aneurysm, implants)...
Trial design
Single group
Treatments tested in this trial
Quadriceps Combined Test
Diagnostic testThe recording of the motor response on the quadriceps is done using self-adhesive surface electrodes on the motor point of the vastus medialis muscles (active electrodes) and on the patella (reference electrode), using a classic electromyography device that allows calculations and measurements of amplitude, duration and speed.
Treatment groups
Trial outcomes
Primary outcomes
Parameters from the QCT (Quadriceps Combined Test)
Measure of amplitude of M
Parameters from the QCT (Quadriceps Combined Test)
Measure of amplitude of M
Parameters from the QCT (Quadriceps Combined Test)
Measure of amplitude of M
Parameters from the QCT (Quadriceps Combined Test)
Measure of amplitude of M
Secondary outcomes
Clinical and paraclinical likely course data
MRC (Medical Research Council) scale for the evaluation of muscular strength. Score from 0 to 5. Higher score means normal movement
Clinical and paraclinical likely course data
ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating) scale score. Score from 0 to 48.
Clinical and paraclinical likely course data
Spirometry data : Slow Vital Capacity
Clinical and paraclinical likely course data
Spirometry data : Maximal Inspiratory Pressure
Sponsors and contacts
Click on the lead sponsor to view all of their trials.